Tirzepatide therapy reduces subclinical leaflet thrombosis and paravalvular leak after transcatheter aortic valve replacement in obese patients: The TAVR-MET trial

What Was Tested

Researchers studied Tirzepatide in this randomized controlled trial publication.

However, its impact on post-TAVR valve performance has not been previously evaluated.

The trial enrolled 260 obese patients (BMI ≥ 30 kg/m2) undergoing transfemoral TAVR across eight high-volume centers.

Who Took Part

The study group was 260 patients.

By PubMed's age tags, the people studied were older adults and people over 80, both men and women.

TAVR-MET was a prospective, randomized, open-label, multicenter trial enrolling obese patients (BMI ≥ 30 kg/m2) undergoing transfemoral TAVR.

Patients were randomized to tirzepatide therapy or standard care.

How the Study Was Run

The researchers set it up as a randomized, open-label and multicenter study.

Because people in this Tirzepatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Tirzepatide study did not mask who received what.

Running at several centres spread the Tirzepatide study over different clinics and patient groups.

The methods mention a period of 12 months.

The primary endpoint was HALT incidence at 6 months assessed by 4D-CT or transesophageal echocardiography (TEE).

Participants were randomized to receive tirzepatide initiated four weeks before TAVR and continued for 12 months, or standard care alone.

What Was Measured

However, its impact on post-TAVR valve performance has not been previously evaluated.

The primary endpoint was the incidence of HALT at six months assessed by advanced imaging.

PubMed files the paper under topics including Aortic Valve, Aortic Valve Insufficiency, Aortic Valve Stenosis, Heart Valve Prosthesis, Obesity, Risk Factors and Thrombosis.

The authors tagged it with the keywords Cardio-metabolic therapy, GLP-1/GIP agonist, Hypoattenuated leaflet thickening, Paravalvular leak, Subclinical leaflet thrombosis and TAVR.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Tirzepatide in 260 patients over 12 months.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Cardiovascular revascularization medicine : including molecular interventions), a journal based in United States.

More context: the Tirzepatide compound page, all human trials.